Get the Stockscreener App
0.712
5.12%
0.0347
After Hours:
.68
-0.032
-4.49%
Verrica Pharmaceuticals Inc stock is traded at $0.712, with a volume of 637.98K.
It is up +5.12% in the last 24 hours and up +2.56% over the past month.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
See More
Previous Close:
$0.6773
Open:
$0.7
24h Volume:
637.98K
Relative Volume:
0.91
Market Cap:
$64.48M
Revenue:
$5.12M
Net Income/Loss:
$-67.00M
P/E Ratio:
-0.4844
EPS:
-1.47
Net Cash Flow:
$-38.94M
1W Performance:
+8.59%
1M Performance:
+2.56%
6M Performance:
-89.89%
1Y Performance:
-87.95%
1-Day Range:
$0.675
$0.7302
1-Week Range:
$0.63
$0.7302
52-Week Range:
$0.6109
$11.41
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Name
Verrica Pharmaceuticals Inc
Sector
Industry
Phone
484-453-3300
Address
10 NORTH HIGH STREET, WEST CHESTER, PA
Compare VRCA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
0.712 | 64.48M | 5.12M | -67.00M | -38.94M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-25-23 | Upgrade | Needham | Hold → Buy |
| Mar-22-23 | Initiated | Jefferies | Buy |
| Feb-13-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-25-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-20 | Initiated | Northland Capital | Outperform |
| Mar-24-20 | Initiated | Needham | Buy |
| Feb-21-19 | Initiated | H.C. Wainwright | Buy |
View All
Verrica Pharmaceuticals Inc Stock (VRCA) Latest News
Verrica reports high response rate in skin cancer study - MSN
Verrica Pharmaceuticals Announces Presentation of Three - GlobeNewswire
Verrica's Skin Cancer Drug Shows 97% Response Rate in Phase 2 Trial, Complete Clearance in Half of Tumors - StockTitan
Certain Pre-Funded Warrants of Verrica Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 20-JAN-2025. - Marketscreener.com
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Shares Bought by Jane Street Group LLC - Defense World
Barclays PLC Grows Position in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) - Defense World
Immedica Pharma to Acquire Marinus Pharmaceuticals in $151 Million Deal - MyChesCo
State Street Corp Buys 61,041 Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) - Defense World
60,000 Shares in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Purchased by Sanctuary Advisors LLC - Defense World
Verrica Pharmaceuticals Reports Progress on Molluscum Treatment and Pipeline Development - MSN
Needham & Company LLC Reiterates Hold Rating for Verrica Pharmaceuticals (NASDAQ:VRCA) - Defense World
Verrica Pharmaceuticals Grants Stock Option to New COO David Zawitz - MSN
Verrica reports rise in YCANTH applicator units in Q4 By Investing.com - Investing.com South Africa
Verrica reports rise in YCANTH applicator units in Q4 - Investing.com
Verrica Provides Business and Operational Update - GlobeNewswire
Verrica Pharma's YCANTH Sales Surge in Q4; Plans Game-Changing Single Applicator Launch for 2025 - StockTitan
GLP-1 Receptor Agonist Market Is Booming Worldwide 2024-2031:Verrica Pharmaceuticals,AbbVie Inc,Glenmark - EIN News
Verition Fund Management LLC Acquires New Holdings in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) - Defense World
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Position Reduced by Fmr LLC - Defense World
Verrica Pharmaceuticals stock hits 52-week low at $0.7 By Investing.com - Investing.com Canada
Verrica Pharmaceuticals stock hits 52-week low at $0.7 - Investing.com
Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Drops By 32.6% - Defense World
Verrica Pharmaceuticals' SWOT analysis: stock faces headwinds amid strategic shift - Investing.com
Verrica Pharmaceuticals' SWOT analysis: stock faces headwinds amid strategic shift By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Inc. Appoints David Zawitz as Chief Operating Officer - Marketscreener.com
GLP-1 Receptor Agonist Market Is Booming Worldwide 2024-2031: Novan Inc., Verrica Pharmaceuticals, AbbVie - EIN News
Verrica Pharmaceuticals appoints new COO By Investing.com - Investing.com Australia
PERCEPTIVE ADVISORS LLC Increases Stake in Verrica Pharmaceutica - GuruFocus.com
Verrica Pharmaceuticals appoints new COO - Investing.com India
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Verrica Pharmaceuticals Appoints New Chief Operating Officer - TipRanks
Verrica Pharmaceuticals Grants 950K Share Options Package to New COO in Key Executive Appointment - StockTitan
Verrica's partner Torii seeks Japan NDA for skin treatment By Investing.com - Investing.com Canada
New Drug Application Submitted in Japan for Verrica Pharmaceuticals’ TO-208 - MyChesCo
Verrica's partner Torii seeks Japan NDA for skin treatment - Investing.com India
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan - The Manila Times
Verrica Pharmaceuticals Announces that Development Partner - GlobeNewswire
Verrica's Partner Files NDA in Japan for Breakthrough Molluscum Treatment, Targeting 1.6M Patient Market - StockTitan
Verrica Pharmaceuticals (FRA:1NE) Debt-to-Revenue : N/A (As of Sep. 2024) - GuruFocus.com
Virpax Pharmaceuticals Announces Positive Results in Study for Long-Lasting Pain Relief Formulation - MSN
Common Warts Pipeline Insights 2024: Therapies, Clinical - openPR
West Chester-based Verrica Pharmaceuticals Expects to Raise $42 Million in Public Stock Offering - VISTA.Today
Latham & Watkins Advises on Verrica Pharmaceuticals Inc.’s Public Offering - Latham & Watkins LLP
Chester County firm expects to raise $42M after trimming staff and naming new CEO - The Business Journals
Verrica Pharmaceuticals Inc Stock (VRCA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):